On a gray April morning better suited to defensive sectors than bold moves, Italy’s Chiesi Group decided to do the opposite and write a $1.9 billion check for KalVista Pharmaceuticals, a specialist in oral therapies for hereditary angioedema (HAE). The deal, struck…